Associated Papers
Innovative Drug and Prodrug Candidates in Cancer Treatment Targeting TP53 Mutations: Challenge and Hope.
Al-Zoubi RM et al.
Drug Development Research, 2026
LINE-1 retrotransposition is a recurrent cause of MET exon 14 skipping in cancer.
Karlow JA et al.
Biorxiv : the Preprint Server for Biology, 2026
Lung cancer-enriched p53 mutants occupy canonical p53 target genes without activating transcription, revealing a distinct loss-of-function behavior.
Tracewell MA et al.
Biorxiv : the Preprint Server for Biology, 2026
Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.
Xu S et al.
Genes & Genomics, 2026
Actionable genomic landscape of biliary tract cancer in the Indian population.
Limaye S et al.
The Oncologist, 2026
ENY2 transcription and export complex 2 subunit deficiency induces nucleolar stress to inhibit tumor progression through NPM1/MDM2/p53-dependent and -independent responses.
Zuo S et al.
Cellular Oncology (dordrecht, Netherlands), 2026
Genetic variants underlying precancerous conditions of hepatocellular carcinoma.
Guerrero JJG et al.
International Journal of Cancer, 2026
Mutant p53 disrupts antioxidant defense in fallopian tube epithelium via GSTAs suppression: A pathway to serous tubal carcinogenesis.
Burnett DB et al.
Free Radical Biology & Medicine, 2026
Mutant p53 Regulates Pyruvate Dehydrogenase Kinase 1 (PDK1) to Promote Proliferation and Migration in Breast Cancer.
Ye Y et al.
Cancer Science, 2026
The molecular mechanism of temperature-dependent p53C phase separation accelerated by oncogenic mutations: insights from all-atom and coarse-grained molecular dynamics simulations.
Duan Z et al.
Physical Chemistry Chemical Physics : Pccp, 2026
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
CP-31398 restored the functional condensates of R175H p53 by stabilizing the zinc-binding domain and 251-258 segment.
Liu Y et al.
Colloids and Surfaces. B, Biointerfaces, 2026
Correlation analysis of TP53 missense mutations and p53 protein expression patterns in endometrial carcinoma.
Yang Y et al.
Human Pathology, 2026
TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.
Liu S et al.
Annals of Hematology, 2026
Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer.
Zhao W et al.
Advanced Science (weinheim, Baden-wurttemberg, Germany), 2026
Mutational patterns and ancestry-linked profiles in a large hepatocellular carcinoma and combined hepatocellular-cholangiocarcinoma cohort.
Gerdes C et al.
Esmo Open, 2026
Construction of Small-Molecule Deubiquitinase-Targeting Chimeras to Reactivate and Stabilize Mutant p53 Y220C in Vitro and in Vivo.
He C et al.
Angewandte Chemie (international Ed. in English), 2026
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion.
Zaghla BKQ et al.
Journal for Immunotherapy of Cancer, 2026
Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells.
Tahaney WM et al.
Breast Cancer Research and Treatment, 2026
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.
Brown JR et al.
Blood, 2026
Oxidative stress-driven transcriptomic remodeling in human astrocytes reveals network signatures associated with neurodegenerative and cardiovascular processes.
Bota PM et al.
Computational and Structural Biotechnology Journal, 2026
Exon-level TP53 alterations and PD-L1 expression identified by pretreatment NGS stratify survival in EGFR-mutant non-small cell lung cancer treated with first-line osimertinib.
Kim SE et al.
Translational Lung Cancer Research, 2025
A Computational Approach for the Prediction of p53 and BCL-2 Protein-Protein Interactions.
Creamer C et al.
International Journal of Molecular Sciences, 2025
Lipid Transfer Proteins and PI4KIIα Generate a Phosphoinositide-Linked Proteome.
Carrillo ND et al.
Biorxiv : the Preprint Server for Biology, 2025
p53: An Immune Ecosystem Manipulator.
Nian Z et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Gain of function p53 mutant R273H confers distinct methylation profiles and consequent YAP/TAZ signaling mediated activation of partial or full EMT states to colon tumours.
Rani H et al.
Epigenetics & Chromatin, 2025
A Primary CNS Sarcoma of the Spinal Cord with DICER1 Mutation: Expanding the Spectrum of DICER1-Driven CNS Sarcomas.
Pasarikovski CR et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, 2025
Integrative sWGS: A New Paradigm for HRD Detection in Ovarian Cancer.
Jinga DC et al.
International Journal of Molecular Sciences, 2025
Mechanistic Insights into the Allosteric Regulation of P53 Y220C by Small-Molecule Stabilizers.
Wen Y et al.
Journal of Chemical Information and Modeling, 2025
Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.
Allsopp RC et al.
Bmc Cancer, 2025
Allosteric and Dominant-Negative Effects in a p53 Core Heterotetramer.
Zhou H et al.
The Journal of Physical Chemistry. B, 2025
Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.
Paulino PJIV et al.
Journal, Genetic Engineering & Biotechnology, 2025
Cancers modulate p53 truncal neoantigen display to evade T cell detection.
Haratani K et al.
Biorxiv : the Preprint Server for Biology, 2025
Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.
Òdena A et al.
Npj Precision Oncology, 2025
Translating genomic insights into therapy: an NGS-based mutation profiling study in breast cancer.
Bhavnagari HM et al.
Medical Oncology (northwood, London, England), 2025
Clinical and molecular determinants of response to maintenance olaparib for primary and recurrent epithelial ovarian carcinoma.
Wagar MK et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025
Clinical and genomic features of Lynch syndrome differ by tumor site and disease spectrum.
Li S et al.
Nature Communications, 2025
Mutant p53 binds RNA to drive mitochondrial dysfunction.
Zhou W et al.
Biorxiv : the Preprint Server for Biology, 2025
Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition.
Liu K et al.
Communications Biology, 2025
Analysis of Concurrent Intracholecystic Papillary Neoplasms and Biliary Intraepithelial Neoplasia Reveals Distinct Histologic and Molecular Profiles.
Malik P et al.
Archives of Pathology & Laboratory Medicine, 2025
Comparative Study of a Variant Neural Relational Inference Deep Learning Model and Dynamical Network Analysis for p53-DNA Allosteric Interactions.
Sun H et al.
Journal of Molecular Biology, 2025
Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers.
Malhotra L et al.
Journal of Biomolecular Structure & Dynamics, 2025
Impact of TP53, KRAS, and APC Mutations on Neoadjuvant Chemotherapy Outcomes in Locally Advanced Rectal Cancer.
Takeda T et al.
Cancer Science, 2025
Somatic mutation and selection at population scale.
Lawson ARJ et al.
Nature, 2025